- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06104215
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
Clinical Study on the Safety and Initial Efficacy of BGT007H Cell Therapy in Patients With Recurrent/Metastatic Refractory Digestive Tract Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221000
- Recruiting
- The Affiliated Hospital of Xuzhou Medical University
-
Contact:
- Li Li, doctor
- Phone Number: +86-516-85609999
- Email: lily9711214@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign a written informed consent;
- Age ≥18 years old, ≤70 years old, male and female;
- Expected survival ≥ 3 months;
- The Eastern Cancer Collaboration (ECOG) physical fitness score was 0-1;
- Biopsy specimen or pathological wax section test (within 3 years before the signing of informed consent) : Target protein test is positive;
- At least one measurable lesion according to RECIST v1.1 solid tumor evaluation criteria;
- Patients with recurrent/metastatic refractory digestive tract tumors (esophageal, gastric, pancreatic, or colorectal cancer) who have previously received second-line or above standard treatment failure or intolerance;
- It is possible to establish a vein access for simple or intravenous blood collection, and there are no other contraindications for blood cell separation;
- having adequate organ and bone marrow function, as defined below: Blood routine examination Neutrophil count (NEU #) ≥1.0×10^9/L Platelet count (PLT) ≥80×10^9/L Hemoglobin concentration ≥90g/L Liver function: subjects without liver metastases Aspartate aminotransferase (AST) ≤2.5× Upper Limit of Normal (ULN) Alanine aminotransferase (ALT) ≤2.5× Upper Limit of Normal (ULN) Total bilirubin (TBIL) ≤1.5×ULN Liver function: Subjects with liver metastases Aspartate aminotransferase (AST) ≤5× Upper limit of normal (ULN) Alanine aminotransferase (ALT) ≤5× Upper limit of normal (ULN) Liver function: Subjects with liver metastases or Gilbert syndrome Total bilirubin (TBIL) ≤2×ULN renal function Creatinine clearance (CCR) ≥50 mL/min Coagulation function International Standardized ratio (INR) ≤1.5×ULN Activated partial thromboplastin time (APTT) ≤1.5×ULN
- Toxic side effects left over from previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) ≤ grade 1 (CTCAE 5.0);
- During the study period and for 6 months after the end of dosing, fertile subjects (both male and female) must use effective medical contraception. For female subjects of reproductive age, a pregnancy test should be performed within 72 hours before the first dose and the result is negative.
Exclusion Criteria:
- Active central nervous system metastases (except those stable after treatment);
- HIV positive, HBsAg positive, HBV DNA copy number positive (quantitative detection ≥1000cps/ml), HCV antibody positive and HCV RNA positive;
- Patients with mental or mental illness who cannot cooperate with treatment and efficacy evaluation;
- Subjects with severe autoimmune diseases and long-term use of immunosuppressants;
- Active or uncontrolled infections requiring systemic treatment during the 14 days prior to enrollment;
Any unstable systemic disease (including but not limited to) :
Active infections (except local infections); unstable angina pectoris; cerebral ischemia or cerebrovascular accident (within 6 months prior to screening); myocardial infarction (within 6 months before screening); Congestive heart failure (New York Heart Association [NYHA] classification ≥III); Severe arrhythmias requiring medical treatment; have a heart condition that requires treatment or uncontrolled hypertension after treatment (blood pressure > 160mmHg/100 mmHg);
- dysfunction of important organs such as lung, brain and kidney;
- The subject has undergone major surgery or severe trauma within 4 weeks prior to receiving cell therapy, or is expected to undergo major surgery during the study period;
- Received any systemic chemotherapy, immunotherapy, or small molecule targeted therapy within 1-2 weeks prior to anapheresis or within 5 half-lives, whichever is shorter;
- The subject currently has or has had other malignant tumors that cannot be cured within 3 years, except cervical carcinoma in situ or basal cell carcinoma of the skin, and other malignant tumors with disease-free survival of more than 5 years;
- Received chimeric antigen receptor modified T cells (including CAR-T, TCR-T) within six months;
- Graft-versus-host disease (GVHD);
- Participants who were receiving systemic steroid therapy prior to screening and who were determined by the investigator to require long-term use of systemic steroid therapy during treatment (except for inhalation or topical use); And subjects treated with systemic steroids within 72 h prior to cell transfusion (except for inhalation or topical use);
- Severe allergies or history of allergies;
- Subjects requiring anticoagulation therapy;
- Pregnant or breastfeeding women, or have a pregnancy plan within six months (for both men and women)
- Researchers believe that there are other reasons for not being included in the treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BGT007H Cell Injection
This is an exploratory study of single-arm, open, modified "3+3" dose escalation.
The BGT007H cell therapy group received five progressively increased dose levels (2.0× 10^8,5.0
×10^8, 1.0× 10^9,3.0
× 10^9,6.0
×10^9) of BGT007H cells.
Each subject was observed for at least 4 weeks after cell transfusion (DLT observation period).
The first two dose groups (2.0×10^8 cells and 5.0×10^8 cells) included 1 subject each, and the other three dose groups were followed by conventional "3+3" dose increments.
|
BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10^8 cells,5.0
×10^8 cells, 1.0× 10^9 cells,3.0 × 10^9 cells,6.0
×10^9 cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity(DLT)
Time Frame: From day 0 to day 28
|
Adverse events related to cell therapy were observed on 28 days after BGT007H injection , as specified in the protocol
|
From day 0 to day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: 12 months
|
The time from the onset of leukocyte apheresis to the appearance of tumor progression or death.
|
12 months
|
Cmax
Time Frame: 12 months
|
The amplification of BGT007H injection in peripheral blood peaked after administration
|
12 months
|
Tmax
Time Frame: 12 months
|
Number of days of peak BGT007H injection expansion after administration
|
12 months
|
ORR
Time Frame: 12 months
|
Proportion of patients who achieved pre-defined tumor volume reduction and maintained the minimum time limit.Imaging examination was performed after administration, and RECIST1.1 evaluation criteria was used for evaluation.
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- BR-BGT-005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Digestive Tract Cancer
-
Institut du Cancer de Montpellier - Val d'AurelleCompleted
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina
-
European Organisation for Research and Treatment...Hoffmann-La Roche; Leap Therapeutics, Inc.WithdrawnEsophageal Cancer | Hepatobiliary Neoplasm | Biliary Tract Cancer | GastroEsophageal Cancer
-
Tianjin Medical University Cancer Institute and...RecruitingAdvanced Biliary Tract CancerChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingAdvanced Biliary Tract CancerChina
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaboratorsRecruitingAdvanced Biliary Tract CancerTaiwan
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingBiliary Tract Cancer (BTC)Taiwan
-
AHS Cancer Control AlbertaCelgeneActive, not recruitingUnresectable Biliary Tract CancerCanada
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Chang... and other collaboratorsActive, not recruitingAdvanced Biliary Tract CancerTaiwan
Clinical Trials on BGT007H Injection
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
National Taiwan University HospitalCompleted
-
Ostfold Hospital TrustOslo University HospitalRecruitingCholecystitis | Gall StoneNorway